drugset / Trial / NCT00480571

Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder

NCT00480571

Phase 2 Completed 90 enrolled BioLineRx, Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

An open-label, multi-center, 6-week, sequential cohort study designed to determine the safety and tolerability of two dose ranges of BL-1020 in hospitalized subjects with chronic schizophrenia or schizo-affective disorder

Timeline

Start
2007-06
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject PERPHENAZINE 4-AMINOBUTYRATE Small molecule